Cost-effectiveness analysis of CYP3A5 genotype-guided tacrolimus dosing in solid organ transplantation using real-world data [0.03%]
基于真实世界数据的CYP3A5基因型指导Tacrolimus剂量个体化在器官移植中的成本效益分析
Kimberly M Deininger,Heather D Anderson,George P Patrinos et al.
Kimberly M Deininger et al.
The objective of this study was to estimate the cost-effectiveness of CYP3A5 genotype-guided tacrolimus dosing in kidney, liver, heart, and lung transplant recipients relative to standard of care (SOC) tacrolimus dosing, from a US healthcar...
Study on genotype and phenotype of novel CYP2D6 variants using pharmacokinetic and pharmacodynamic models with metoprolol as a substrate drug [0.03%]
基于美托洛尔的药动学和药效学模型研究新型CYP2D6变异体的基因型与表型关系
Jianchang Qian,Tao Xu,Peipei Pan et al.
Jianchang Qian et al.
To investigate the pharmacokinetic and pharmacodynamic profiles of volunteers carrying CYP2D6 genotypes with unknow metabolic phenotypes, a total of 22 volunteers were recruited based on the sequencing results. Peripheral blood and urine sa...
Polygenic scores for cardiovascular risk factors improve estimation of clinical outcomes in CCB treatment compared to pharmacogenetic variants alone [0.03%]
与仅使用药物基因组变异相比，心血管风险因素的多基因评分可改善钙通道阻滞剂治疗的临床结果估算
Deniz Türkmen,Jack Bowden,Jane A H Masoli et al.
Deniz Türkmen et al.
Pharmacogenetic variants are associated with clinical outcomes during Calcium Channel Blocker (CCB) treatment, yet whether the effects are modified by genetically predicted clinical risk factors is unknown. We analyzed 32,000 UK Biobank par...
Pharmacogenomic study-A pilot study of the effect of pharmacogenomic phenotypes on the adequate dosing of verapamil for migraine prevention [0.03%]
药理基因组学研究-药理基因表型对偏头痛预防用药维拉帕米合理剂量影响的试点研究
Yi-Chieh Chen,Han Wang,Jayawant N Mandrekar et al.
Yi-Chieh Chen et al.
Objective: To investigate factors affecting the efficacy and tolerability of verapamil for migraine prevention using individual pharmacogenomic phenotypes. ...
Cost-utility analysis of pharmacogenomics-guided tacrolimus treatment in Austrian kidney transplant recipients participating in the U-PGx PREPARE study [0.03%]
奥地利U-PGx PREPARE研究中肾移植受者的他克莫司治疗的药物基因组学引导的成本效益分析
Vasileios Fragoulakis,Margarita-Ioanna Koufaki,Candace Joefield-Roka et al.
Vasileios Fragoulakis et al.
Chronic kidney disease (CKD) is a global health issue. Kidney failure patients may undergo a kidney transplantation (KTX) and prescribed an immunosuppressant medication i.e., tacrolimus. Tacrolimus' efficacy and toxicity varies among patien...
A review of real-world evidence on preemptive pharmacogenomic testing for preventing adverse drug reactions: a reality for future health care [0.03%]
预防药物不良反应的前瞻性药物基因组学检测的真实世界证据综述：未来的医疗现实
Santenna Chenchula,Shubham Atal,Chakradhara Rao S Uppugunduri
Santenna Chenchula
Adverse drug reactions (ADRs) are a significant public health concern and a leading cause of hospitalization; they are estimated to be the fourth leading cause of death and increasing healthcare costs worldwide. Carrying a genetic variant c...
Network pharmacology prediction, molecular docking and in vitro experiment explored the potential mechanism of Gaoyuan'an capsule in improving hypoxia tolerance [0.03%]
网络药理学预测、分子对接及体外实验探讨高原安胶囊提高缺氧耐受力的潜在机制
Tianbo Jin,Xiaoli Liu,Yuhe Wang et al.
Tianbo Jin et al.
Background: Tibetan medicine Gaoyuan'an capsule (GYAC) is widely used to prevent pulmonary edema at high altitude, but the specific mechanism has not been explored. In this study, we analyzed the mechanism of GYAC in hypo...
Being precise with anticoagulation to reduce adverse drug reactions: are we there yet? [0.03%]
为了减少药物不良反应的精确抗凝治疗：我们达到目标了吗？
Benjamin Cross,Richard M Turner,J Eunice Zhang et al.
Benjamin Cross et al.
Anticoagulants are potent therapeutics widely used in medical and surgical settings, and the amount spent on anticoagulation is rising. Although warfarin remains a widely prescribed oral anticoagulant, prescriptions of direct oral anticoagu...
Pharmacogenetic and clinical risk factors for bevacizumab-related gastrointestinal hemorrhage in prostate cancer patients treated on CALGB 90401 (Alliance) [0.03%]
前列腺癌患者接受CALGB 90401（联盟）治疗时，与贝伐单抗相关的胃肠道出血的药理遗传学和临床风险因素
Jai N Patel,Chen Jiang,Kouros Owzar et al.
Jai N Patel et al.
The objective of this study was to discover clinical and pharmacogenetic factors associated with bevacizumab-related gastrointestinal hemorrhage in Cancer and Leukemia Group B (Alliance) 90401. Patients with metastatic castration-resistant ...
Upregulation of p300 in paclitaxel-resistant TNBC: implications for cell proliferation via the PCK1/AMPK axis [0.03%]
紫杉醇耐药TNBC中p300的上调：通过PCK1/AMPK途径影响细胞增殖的意义
Peng-Wei Zhao,Jia-Xian Cui,Xiu-Mei Wang
Peng-Wei Zhao
Objective: To explore the role of p300 in the context of paclitaxel (PTX) resistance in triple-negative breast cancer (TNBC) cells, focusing on its interaction with the phosphoenolpyruvate carboxykinase 1 (PCK1)/adenosine...